The P-III (ECZTRA 3) trial evaluates tralokinumab-ldrm (300mg) + TCS in 380 adult patients with AD
The results showed an improvement in extent & severity of AD, sleep interference & QoL @32wks., 70.2% of patient achieved improvement of ≥75% & 50.4% in EASI-75 & EASI-90; 70.8% in weekly avg. Eczema-related Sleep Interference NRS; 66.8% in DLQI over baseline. The results were published in American Journal of Clinical Dermatology
At 16wk., 89.9% achieved an improvement in one of three disease measures incl. AD extent & severity (≥50% improvement in EASI-50); pruritus (≥3-point in weekly average Worst Daily Pruritus NRS); QoL (≥4-point in DLQI score), 75.3% achieved EASI-50 with improvements in pruritus or QoL
Ref: Bussinesswire | Image: LEO Pharma
